TAG:
cap
How Could So Many Labs Violate California Law?
By Robert Michel | From the Volume XVII No. 18 – December 27, 2010 Issue
CEO SUMMARY: If a 40-year-old state law on Medi-Cal pricing was known to regulators and clinical laboratories alike, how did the legal and compliance departments of so many laboratories—staffed by some of the smartest legal minds in California and nationally—interpret the law…
Did Qui Tam Suit Trigger Medi-Cal Price Concerns?
By Robert Michel | From the Volume XVII No. 18 – December 27, 2010 Issue
CEO SUMMARY: It is easy to track backwards to understand why the California Department of Healthcare Services (DHCS) began aggressive enforcement of its interpretation of statute 51501(a) against a number of labs this summer. DHCS officials were given a full education and a roadm…
Our Top Ten Lab Stories Highlight Major Changes
By Robert Michel | From the Volume XVII No. 17 – December 6, 2010 Issue
CEO SUMMARY: What makes 2010 a watershed year for the laboratory testing industry is enactment of the 2,700-page Patient Protection and Affordable Care Act (PPACA). Even if parts of this bill are repealed, the remaining parts of the massive legislation will trigger major changes …
FTC Opposes LabCorp’s Acquisition of Westcliff
By Robert Michel | From the Volume XVII No. 17 – December 6, 2010 Issue
CEO SUMMARY: On November 30, FTC commissioners filed an administrative complaint opposing Laboratory Corporation of America’s acquisition of Westcliff Medical Laboratories, Inc., on the grounds that it “violates antitrust laws and would lead to higher prices and lower quality…
Gauging the Prospects For Anatomic Pathology
By Robert Michel | From the Volume XVII No. 16 – November 15, 2010 Issue
CEO SUMMARY: More buyers are crowding into the lab testing industry and looking to acquire anatomic pathology testing companies. These buyers are willing to pay strong prices to acquire AP labs and companies which they determine to be a strategic fit. All of this acquisition acti…
Whole Genome Sequencing: Is It Ready for Prime Time?
By Robert Michel | From the Volume XVII No. 16 – November 15, 2010 Issue
CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagn…
Several Laboratory Companies On Road to Public Stock Offering
By Robert Michel | From the Volume XVII No. 16 – November 15, 2010 Issue
ONE OF THE FEW PUBLIC STOCK OFFERINGS involving a lab testing company was completed last Wednesday. Exact Sciences, Inc., of Madison, Wisconsin sold $69 million worth of new shares to the public. Exact Sciences has proprietary diagnostic technology that it describes as “for noninv…
GE Pulls Plug on Its LIS, No Support after July 2013
By Robert Michel | From the Volume XVII No. 16 – November 15, 2010 Issue
CEO SUMMARY: Not in recent memory has a laboratory information system (LIS) product been pulled from the market. That is why the announcement by GE Healthcare that it would no longer service or support its Centricity Ultra Laboratory product after July 23, 2013, has caused a stir…
Tapping Molecular Pathology’s New Gold Mine
By R. Lewis Dark | From the Volume XVII No. 16 – November 15, 2010 Issue
IN ONE SENSE, WE CAN SAY THAT THE DECADE OF 2001 THROUGH 2010 was bookended by two one-half billion dollar anatomic pathology acquisitions. Each transaction was a powerful signal to Wall Street investors. Unfortunately, most pathologists are not tuned into that signal and so continue to miss the mess…
Growing Role for Digital Image Analysis in Pathology
By Robert Michel | From the Volume XVII No. 15 – October 25, 2010 Issue
CEO SUMMARY: For more than three years, pathologists at Washington University in St. Louis have worked with several different scanning products and digital pathology systems. Step-by-step, the Pathology Department has learned important lessons in how to capture digital images, ar…
CURRENT ISSUE

Volume XXXII, No. 12 – August 25, 2025
In an exclusive interview, a laboratory industry M&A specialist discusses what’s driving lab outreach sales to national lab companies. Also, The Dark Report analyzes ways in which pathology and clinical labs can profitably partner with pharmaceutical companies.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized